Industry
Biotechnology
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
June 18, 2024 | 1:28 pm
Portfolio Pulse from Benzinga Newsdesk
June 11, 2024 | 9:18 am
Portfolio Pulse from Benzinga Newsdesk
June 04, 2024 | 10:38 am
Portfolio Pulse from Benzinga Newsdesk
June 03, 2024 | 11:45 am
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 2:56 pm
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 11:36 am
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 1:28 pm
Portfolio Pulse from Benzinga Newsdesk
May 03, 2024 | 8:11 pm
Portfolio Pulse from Benzinga Newsdesk
April 29, 2024 | 7:51 pm
Portfolio Pulse from Benzinga Newsdesk
April 29, 2024 | 12:45 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.